Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Zilli T, Franzese C, Bottero M, Giaj-Levra N, Förster R, Zwahlen D, Koutsouvelis N, Bertaut A, Blanc J, Roberto D'agostino G, Alongi F, Guckenberger M, Scorsetti M, Miralbell R.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33011-7. doi: 10.1016/j.radonc.2019.07.018. [Epub ahead of print]

PMID:
31431369
2.

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.

Zilli T, Scorsetti M, Zwahlen D, Franzese C, Förster R, Giaj-Levra N, Koutsouvelis N, Bertaut A, Zimmermann M, D'Agostino GR, Alongi F, Guckenberger M, Miralbell R.

Radiat Oncol. 2018 Sep 4;13(1):166. doi: 10.1186/s13014-018-1112-0. Erratum in: Radiat Oncol. 2018 Sep 19;13(1):182.

3.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.

Morton G, Chung HT, McGuffin M, Helou J, D'Alimonte L, Ravi A, Cheung P, Szumacher E, Liu S, Al-Hanaqta M, Zhang L, Mamedov A, Loblaw A.

Radiother Oncol. 2017 Jan;122(1):87-92. doi: 10.1016/j.radonc.2016.10.019. Epub 2016 Nov 4.

PMID:
27823821
4.

A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results.

Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, Piet AHM, Meijnen P, Bakker van der Jagt MAB, Fraikin T, Slotman BJ, van Moorselaar RJA, Lagerwaard FJ.

Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33640-5. doi: 10.1016/j.ijrobp.2019.08.007. [Epub ahead of print]

PMID:
31419510
5.

Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.

Gomez-Iturriaga A, Casquero F, Pijoan JI, Minguez P, Espinosa JM, Irasarri A, Bueso A, Cacicedo J, Buchser D, Bilbao P.

Radiother Oncol. 2018 Feb;126(2):278-282. doi: 10.1016/j.radonc.2017.10.039. Epub 2017 Nov 15.

PMID:
29153462
6.

Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M, Konishi K, Yoshioka Y, Ogawa K.

J Radiat Res. 2014 Nov;55(6):1114-21. doi: 10.1093/jrr/rru048. Epub 2014 Jun 23.

7.

Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.

Hwang ME, Mayeda M, Liz M, Goode-Marshall B, Gonzalez L, Elliston CD, Spina CS, Padilla OA, Wenske S, Deutsch I.

Radiat Oncol. 2019 Aug 2;14(1):136. doi: 10.1186/s13014-019-1346-5.

8.

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.

Repka MC, Guleria S, Cyr RA, Yung TM, Koneru H, Chen LN, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch J, Collins SP.

Front Oncol. 2016 May 18;6:122. doi: 10.3389/fonc.2016.00122. eCollection 2016.

9.

Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

Dubouloz A, Rouzaud M, Tsvang L, Verbakel W, Björkqvist M, Linthout N, Lencart J, Pérez-Moreno JM, Ozen Z, Escude L, Zilli T, Miralbell R.

Radiat Oncol. 2018 Jun 19;13(1):114. doi: 10.1186/s13014-018-1059-1.

10.

Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?

Roy S, Morgan SC.

Curr Urol Rep. 2019 Jul 29;20(9):53. doi: 10.1007/s11934-019-0918-0. Review.

PMID:
31359187
11.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
12.

Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.

Fuller DB, Naitoh J, Lee C, Hardy S, Jin H.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97. doi: 10.1016/j.ijrobp.2007.11.067.

PMID:
18374232
13.

Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.

Goddard LC, Brodin NP, Bodner WR, Garg MK, Tomé WA.

Br J Radiol. 2018 May;91(1085):20180010. doi: 10.1259/bjr.20180010. Epub 2018 Mar 2.

14.

Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.

Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C, Dellas K, Baumann R, Rödel C, Hildebrandt G, Jünemann KP, Merseburger AS, Katz A, Ziegler A, Blanck O, Dunst J.

Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2.

15.

A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.

Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A.

BMC Urol. 2013 Oct 17;13:49. doi: 10.1186/1471-2490-13-49.

16.

Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?

Gonzalez-Motta A, Roach M 3rd.

Pract Radiat Oncol. 2018 May - Jun;8(3):185-202. doi: 10.1016/j.prro.2017.11.008. Epub 2017 Dec 2. Review.

17.

A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Kole TP, Nichols RC, Lei S, Wu B, Huh SN, Morris CG, Lee S, Tong M, Mendenhall NP, Dritschilo A, Collins SP.

Acta Oncol. 2015 Jun;54(6):825-31. doi: 10.3109/0284186X.2014.953260. Epub 2014 Sep 17.

PMID:
25227898
18.

Single institution's dosimetry and IGRT analysis of prostate SBRT.

Wu QJ, Li T, Yuan L, Yin FF, Lee WR.

Radiat Oncol. 2013 Sep 13;8:215. doi: 10.1186/1748-717X-8-215.

19.

Validation of dynamic treatment-couch tracking for prostate SBRT.

Ehrbar S, Schmid S, Jöhl A, Klöck S, Guckenberger M, Riesterer O, Tanadini-Lang S.

Med Phys. 2017 Jun;44(6):2466-2477. doi: 10.1002/mp.12236. Epub 2017 Apr 25.

PMID:
28339109
20.

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9.

PMID:
11163498

Supplemental Content

Support Center